{"id":"tislelizumab-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Cough"},{"rate":"10-20%","effect":"Pyrexia"},{"rate":"5-15%","effect":"Decreased appetite"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-15%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, tislelizumab prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are expressed on the surface of cancer cells. This blockade restores the immune system's ability to recognize and attack cancer cells, leading to anti-tumor activity.","oneSentence":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:15.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic esophageal squamous cell carcinoma"},{"name":"Locally advanced or metastatic urothelial carcinoma"},{"name":"Adenocarcinoma of the stomach"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"},{"name":"Non-small cell lung cancer"},{"name":"Urothelial carcinoma"}]},"trialDetails":[{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT06563245","phase":"PHASE2, PHASE3","title":"Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2024-09-25","conditions":"Classical Hodgkin Lymphoma, Child, Adolescent","enrollment":96},{"nctId":"NCT07043400","phase":"PHASE3","title":"A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-08-27","conditions":"Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT07331155","phase":"PHASE2","title":"A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-02-26","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT07413042","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-01-20","conditions":"SCLC, Extensive Stage","enrollment":24},{"nctId":"NCT06562647","phase":"NA","title":"SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cell Origin Biotech (Hangzhou) Co., Ltd.","startDate":"2023-04-12","conditions":"Treatment Related Cancer, Ovarian Cancer","enrollment":2},{"nctId":"NCT07390383","phase":"PHASE2","title":"A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2026-03-25","conditions":"Advanced Solid Tumour","enrollment":110},{"nctId":"NCT07396090","phase":"NA","title":"Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-20","conditions":"Advanced Solid Tumor","enrollment":13},{"nctId":"NCT07385703","phase":"PHASE3","title":"Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2026-03","conditions":"Adenocarcinoma","enrollment":752},{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07376499","phase":"PHASE2","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2026-01-25","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT07341360","phase":"EARLY_PHASE1","title":"Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-10-13","conditions":"Pseudomyxoma Peritonei","enrollment":10},{"nctId":"NCT07330037","phase":"PHASE2","title":"TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-01","conditions":"NSCLC","enrollment":41},{"nctId":"NCT07304258","phase":"PHASE2","title":"A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University","startDate":"2025-12-12","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":30},{"nctId":"NCT06825494","phase":"PHASE1, PHASE2","title":"Clinical Studies for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-04-08","conditions":"Advanced Solid Tumor","enrollment":194},{"nctId":"NCT03736889","phase":"PHASE2","title":"Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors","status":"RECRUITING","sponsor":"BeiGene","startDate":"2018-09-19","conditions":"MSI-H/dMMR Solid Tumors","enrollment":200},{"nctId":"NCT05886439","phase":"PHASE1, PHASE2","title":"LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-05-11","conditions":"Lung Cancer","enrollment":60},{"nctId":"NCT05516914","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2022-09-01","conditions":"Malignant Tumors","enrollment":490},{"nctId":"NCT07243691","phase":"NA","title":"Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT07196540","phase":"PHASE2","title":"IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-09-26","conditions":"Digestive System Neoplasms","enrollment":78},{"nctId":"NCT04047186","phase":"PHASE2","title":"Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules","status":"COMPLETED","sponsor":"XiangNing Fu","startDate":"2019-07-01","conditions":"Multiple Pulmonary Nodules","enrollment":12},{"nctId":"NCT07185243","phase":"NA","title":"A Study to Evaluate Combination Therapy of Oncolytic Vaccinia Virus (hV01) and PD-1 Inhibitor in Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Hangzhou Converd Co., Ltd.","startDate":"2025-06-23","conditions":"Advanced Solid Tumors","enrollment":24},{"nctId":"NCT05267054","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab","status":"COMPLETED","sponsor":"BeiGene","startDate":"2022-04-25","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma","enrollment":53},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT06091943","phase":"PHASE1","title":"Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-11-16","conditions":"Non-small Cell Lung Cancer","enrollment":62},{"nctId":"NCT07077369","phase":"PHASE1","title":"WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":10},{"nctId":"NCT06793917","phase":"PHASE3","title":"Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-06-07","conditions":"Gastric Cancer","enrollment":269},{"nctId":"NCT06617936","phase":"PHASE2","title":"Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.","status":"RECRUITING","sponsor":"Hua Zhang","startDate":"2024-08-27","conditions":"Unresectable Non-small Cell Lung Cancer","enrollment":36},{"nctId":"NCT06379087","phase":"PHASE2","title":"Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC","status":"RECRUITING","sponsor":"Ji Yongling","startDate":"2024-05-01","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04746924","phase":"PHASE3","title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2021-06-08","conditions":"Non-small Cell Lung Cancer, NSCLC","enrollment":662},{"nctId":"NCT07010120","phase":"PHASE1, PHASE2","title":"A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-06-10","conditions":"HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy","enrollment":29},{"nctId":"NCT06997913","phase":"","title":"Adjuvant Immunotherapy Combined With ChemoRadiation for Patients With High-risk Resectable Extrahepatic Cholangiocarcinoma（AICRC）","status":"ENROLLING_BY_INVITATION","sponsor":"Hengchao Yu","startDate":"2025-03-15","conditions":"Lymph Node Metastasis, Neurovascular Invasion, Pathology Showed R1 Resection","enrollment":10},{"nctId":"NCT06659042","phase":"PHASE2","title":"Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2024-11-20","conditions":"Lung Cancer, Non-Small Cell","enrollment":32},{"nctId":"NCT06332274","phase":"PHASE3","title":"tislelizUMaB in canceR Patients With molEcuLar residuaL Disease","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-04-16","conditions":"Cancer, Lung Cancer, Colo-rectal Cancer","enrollment":717},{"nctId":"NCT04261439","phase":"PHASE1","title":"A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-02-27","conditions":"In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT03957590","phase":"PHASE3","title":"A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-06-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":370},{"nctId":"NCT06497010","phase":"EARLY_PHASE1","title":"An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment","status":"RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2024-08-29","conditions":"Advanced Solid Tumor","enrollment":40},{"nctId":"NCT06951841","phase":"PHASE4","title":"Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-04-30","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT05984602","phase":"PHASE1","title":"A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-07-14","conditions":"Pancreatic Cancer","enrollment":10},{"nctId":"NCT06431243","phase":"PHASE1, PHASE2","title":"A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-05-08","conditions":"Advanced Solid Tumor","enrollment":132},{"nctId":"NCT06914687","phase":"PHASE2","title":"Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-03-30","conditions":"Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis","enrollment":30},{"nctId":"NCT06416410","phase":"PHASE3","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-08-07","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":392},{"nctId":"NCT06883552","phase":"PHASE2","title":"An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-10-01","conditions":"Lung Cancer (NSCLC)","enrollment":21},{"nctId":"NCT06541639","phase":"PHASE1","title":"EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors","status":"RECRUITING","sponsor":"Peking University","startDate":"2025-03-04","conditions":"Advanced or Recurrent Solid Tumors","enrollment":78},{"nctId":"NCT06876688","phase":"PHASE2","title":"Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-11-30","conditions":"CNS Lymphoma","enrollment":30},{"nctId":"NCT06868732","phase":"PHASE1","title":"Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-03-12","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":288},{"nctId":"NCT05303090","phase":"PHASE1","title":"Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-31","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":56},{"nctId":"NCT04948697","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-08-20","conditions":"Advanced Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT05823311","phase":"PHASE3","title":"Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-01","conditions":"Advanced Cholangiocarcinoma","enrollment":80},{"nctId":"NCT04732494","phase":"PHASE2","title":"Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-03-31","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":125},{"nctId":"NCT06472713","phase":"PHASE2","title":"Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2024-07-20","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":32},{"nctId":"NCT06749886","phase":"PHASE2","title":"An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting","status":"RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-11-19","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT06741982","phase":"PHASE1","title":"A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-12-15","conditions":"HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy","enrollment":21},{"nctId":"NCT06704620","phase":"PHASE3","title":"Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-12","conditions":"Advanced and Metastatic NSCLC","enrollment":430},{"nctId":"NCT06690476","phase":"EARLY_PHASE1","title":"Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Peking University","startDate":"2024-10-10","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":74},{"nctId":"NCT06602011","phase":"","title":"Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-09-30","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06607926","phase":"NA","title":"Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2024-10-15","conditions":"Resectable Non-Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06441110","phase":"PHASE3","title":"Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2023-06-01","conditions":"Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active","enrollment":76},{"nctId":"NCT06387056","phase":"PHASE2","title":"Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-04-01","conditions":"Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer","enrollment":40},{"nctId":"NCT06375109","phase":"PHASE2","title":"PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital, Capital Medical University","startDate":"2024-04-16","conditions":"Limited-stage Small-cell Lung Cancer","enrollment":60},{"nctId":"NCT06356701","phase":"PHASE1","title":"Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2024-04-15","conditions":"Long-Term Effects Secondary to Cancer Therapy","enrollment":120},{"nctId":"NCT06253598","phase":"PHASE2","title":"Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Bengbu Medical University","startDate":"2024-03-30","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT06210334","phase":"PHASE2","title":"HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)","status":"UNKNOWN","sponsor":"Li Xiao Wei","startDate":"2024-03","conditions":"Hepatocellular Carcinoma With PVTT","enrollment":54},{"nctId":"NCT06235918","phase":"PHASE2","title":"Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xiang Lu","startDate":"2023-01-01","conditions":"Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma","enrollment":30},{"nctId":"NCT04914390","phase":"PHASE2","title":"A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2023-09-15","conditions":"Triple-negative Breast Cancer","enrollment":32},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06132698","phase":"PHASE2","title":"Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2023-11-30","conditions":"NSCLC Associated With Leptomeningeal Metastases","enrollment":17},{"nctId":"NCT05588219","phase":"PHASE2","title":"Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Yong Zhang,MD","startDate":"2022-12-01","conditions":"Uterine Cervical Neoplasms","enrollment":30},{"nctId":"NCT06136910","phase":"PHASE1, PHASE2","title":"Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-05-09","conditions":"Untreated Advanced Non-small Cell Lung Cancer","enrollment":30},{"nctId":"NCT05466474","phase":"PHASE2","title":"PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2022-12-30","conditions":"Advanced Melanoma","enrollment":40},{"nctId":"NCT05120375","phase":"PHASE1","title":"Assessment of Safety and Preliminary Efficacy With BAT6021 in Solid Tumor Patients in China","status":"TERMINATED","sponsor":"Bio-Thera Solutions","startDate":"2022-02-17","conditions":"Solid Tumor","enrollment":5},{"nctId":"NCT06039891","phase":"PHASE2","title":"Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-10-01","conditions":"Cervical Cancer","enrollment":55},{"nctId":"NCT05823987","phase":"PHASE2","title":"Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-05-16","conditions":"Advanced Biliary Tract Cancer","enrollment":25},{"nctId":"NCT05751265","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-07-01","conditions":"Gastric Cancer","enrollment":39},{"nctId":"NCT05527808","phase":"NA","title":"A Single-arm Exploratory Study of Neoadjuvant Therapy","status":"UNKNOWN","sponsor":"Jun Liu","startDate":"2022-08-01","conditions":"Lung Adenocarcinoma","enrollment":28},{"nctId":"NCT05420584","phase":"PHASE2","title":"Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2022-11-29","conditions":"Rectal Neoplasms","enrollment":83},{"nctId":"NCT05699811","phase":"PHASE1, PHASE2","title":"IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-02-23","conditions":"Locally Advanced or Metastatic Solid Tumors","enrollment":40},{"nctId":"NCT04652440","phase":"PHASE1, PHASE2","title":"Ablation Combined With PD-1 in HCC: Phase II Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-12-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05811793","phase":"NA","title":"Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Nanchang University","startDate":"2023-04-15","conditions":"Glioblastoma","enrollment":36},{"nctId":"NCT05809336","phase":"PHASE2, PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":"Advanced Solid Tumor","enrollment":172},{"nctId":"NCT05303844","phase":"PHASE1","title":"Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-04-02","conditions":"Refractory Malignant Ascites","enrollment":25},{"nctId":"NCT04663035","phase":"PHASE2","title":"Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC","status":"UNKNOWN","sponsor":"Ming Zhao","startDate":"2020-12-21","conditions":"Recurrent Hepatocellular Carcinoma","enrollment":120},{"nctId":"NCT05536102","phase":"PHASE2","title":"The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-09-05","conditions":"Gastric Cancer","enrollment":38},{"nctId":"NCT05675462","phase":"PHASE1","title":"Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-03-01","conditions":"Hepatocellular Carcinoma","enrollment":25},{"nctId":"NCT03287427","phase":"PHASE1","title":"MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2018-08-22","conditions":"Colorectal Cancer, Adenoid Cystic Carcinoma","enrollment":27},{"nctId":"NCT05718167","phase":"PHASE3","title":"TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-02","conditions":"Advanced Squamous Non-Small Cell Lung Carcinoma","enrollment":570},{"nctId":"NCT05445648","phase":"PHASE2","title":"Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2023-02","conditions":"Urinary Bladder Neoplasms","enrollment":65},{"nctId":"NCT05505877","phase":"PHASE1, PHASE2","title":"Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Gopherwood Biotech Co., Ltd.","startDate":"2022-09-10","conditions":"Advanced Solid Tumor","enrollment":160},{"nctId":"NCT04924179","phase":"PHASE2","title":"Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2021-06-01","conditions":"Patients With Advanced Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT05441046","phase":"PHASE1","title":"Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors","status":"UNKNOWN","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2022-06-07","conditions":"Malignant Solid Tumors","enrollment":120},{"nctId":"NCT05027100","phase":"NA","title":"Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC","status":"UNKNOWN","sponsor":"Haibo Zhang","startDate":"2021-09-30","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":33},{"nctId":"NCT04973306","phase":"PHASE2, PHASE3","title":"Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-02","conditions":"Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III","enrollment":176},{"nctId":"NCT05346952","phase":"PHASE3","title":"A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-01-25","conditions":"Advanced Non-squamous Non-small Cell Lung Cancer","enrollment":390},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT04981665","phase":"PHASE2","title":"A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-11-08","conditions":"Hepatocellular Carcinoma, Adjuvant Therapy","enrollment":50},{"nctId":"NCT04899427","phase":"PHASE2","title":"Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-03-24","conditions":"Primary Central Nervous System Lymphoma","enrollment":32},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04498793","phase":"PHASE2","title":"Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-09","conditions":"HER2-negative Breast Cancer","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tislelizumab","BGB-A317","BeiGene","Dacarbazine"],"phase":"phase_3","status":"active","brandName":"Tislelizumab Injection","genericName":"Tislelizumab Injection","companyName":"Nanjing Leads Biolabs Co.,Ltd","companyId":"nanjing-leads-biolabs-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tislelizumab is a monoclonal antibody that targets PD-1, a protein on the surface of immune cells, to inhibit the immune system's attack on cancer cells. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic esophageal squamous cell carcinoma, Locally advanced or metastatic urothelial carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}